BOULDER — SomaLogic, a diagnostics company that analyzes individual protein information rather than genomes, is using a $162 million investment to bring its complete diagnostic exam commercially available.
The Boulder-based biotech company filed a Form D with the U.S. Securities and Exchange Commission for more than $162,927,000, with $161 million coming from the investment of Chinese company iCarbonX in May.
The iCarbonX investment gives SomaLogic the runway it needs to bring its diagnostic exam, SomaScan, to customers, said Fintan Steele, SomaLogic’s chief of corporate communications and culture.
SomaLogic is a proteomics company, which means it studies the thousands of proteins that are in the blood system and use them to draw insights on a person’s health.
Steel likened what many personal health companies are studying — genetics and DNA — to the body what a blueprint is to a building or vehicle.
“If you look at an older building’s blueprints, you’re not going to see the wear-and-tear, the leaky pipes, all those things that matter,” Steele said. “Same with cars, there are sensors that come on and say something is not quite right. You can look at the car’s wiring diagram and not have an idea, you need the sensors to say something is wrong with the parts. What’s the equivalent in humans is the molecules that make us up, and those are proteins.”
By studying and analyzing proteins, SomaLogic is able to identify what is going on in a body in real-time.
Anything from a high-fat diet, adding a fitness regimen or developing cancer cells can show changes to proteins in the blood system. Studying those changes can show where a patient is today and…
click here to read more.